Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with advanced (FIGO stage III or IV) or recurrent endometrial cancer
- People with any type of endometrial carcinoma (all tissue types are considered)
- People whose treatment plan includes any form of hormonal therapy
- People who have had a tissue sample (biopsy) taken within 120 days before starting hormonal therapy, with no other cancer treatments received between the biopsy and the start of hormonal therapy
Who may not be able to join:
- People who had hormonal therapy started after the complete surgical removal of their endometrial cancer
- People who are also using hormonal therapy for a different medical reason at the same time
- People whose diagnosis is endometrial sarcoma or endometrial stromal cell sarcoma (these are different tumour types from endometrial carcinoma)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hanny Pijnenborg, MD PhD, Radboud University Medical Center
Phone: +31243616683
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Response rate; Progression free survival; Clinical benefit rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.